Shares of CardioVascular BioTherapeutics Inc. (OTCBB: CVBT) rose 16.3 percent Friday to $1.07 due to highlights of its new angiogenesis treatment for those suffering from heart disease.Cardiovascular disease is no doubt a big issue for not only those inflicted with it, but also for a highly scrutinized healthcare system, due to the cost of necessary treatments. This disease strikes over 36 percent of the population in the U.S., resulting in 2,400 deaths each day. With this in mind, people in the medical industry have been waiting a long time for a better approach to angiogenesis treatment, which is the growth of new blood vessels used to alleviate the decreased blood flow for patients with the disease.
CVBT, a biopharmaceutical company dealing with the production of protein drugs to treat cardiovascular disease, believes it has come up with new technology that will serve as an economic approach to treating the disease.
Fibroblast Growth Factor 1 (FGF-1), the new active pharmaceutical protein developed by CVBT, will stimulate new blood vessel growth. Currently, CVBT is working on ways to develop this protein into an injectable form and has passed the FDA-authorized Phase I study with FGF-1 administered to patients with severe Coronary Heart Disease. Studies have shown that FGF-1 can be applied to multiple tissues in the body that become injured due to decreased blood flow.